Zurcher Kantonalbank Zurich Cantonalbank Has $13.63 Million Holdings in Humana Inc. (NYSE:HUM)

Zurcher Kantonalbank Zurich Cantonalbank reduced its holdings in Humana Inc. (NYSE:HUM) by 19.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,738 shares of the insurance provider’s stock after selling 13,324 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Humana were worth $13,634,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Transcend Capital Advisors LLC lifted its holdings in Humana by 399.7% during the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock worth $924,000 after buying an additional 2,914 shares in the last quarter. FNY Investment Advisers LLC lifted its holdings in Humana by 6,647.5% during the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock worth $6,916,000 after buying an additional 26,856 shares in the last quarter. Retirement Systems of Alabama lifted its holdings in Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after buying an additional 192,801 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Humana by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock worth $244,811,000 after buying an additional 65,735 shares in the last quarter. Finally, PDT Partners LLC lifted its holdings in Humana by 190.0% during the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock worth $1,286,000 after buying an additional 2,660 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.32% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $249.32 on Thursday. The firm has a market cap of $30.08 billion, a PE ratio of 25.06, a PEG ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a fifty day moving average price of $271.59 and a 200 day moving average price of $281.42.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.42%. Humana’s dividend payout ratio is 35.58%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research reports. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Truist Financial upped their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Piper Sandler upped their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Finally, Barclays upped their target price on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.